BSX · News · 20260805N

Competition and Market Share

BOSTON SCIENTIFIC CORP · 2026-08-05 · Importance 26 · Surprise 24

Third-party analysis cited share losses for Boston Scientific in electrophysiology (EP), indicating competitive pressure in cardiac rhythm procedures. The commentary also identified weakness in the WATCHMAN device franchise, which is used for left atrial appendage closure. Medtronic’s Affera mapping and ablation system with the Sphere-9 catheter received a European CE-mark expansion for ventricular arrhythmia treatment, potentially increasing competition in EP ablation.

Key facts

• Michael F. Mahoney increased his direct ownership to over 1.59 million shares and indirectly acquired 22,119 shares through a 401(k) retirement plan rebalancing. source
• Boston Scientific director David C. Habiger reported open-market purchases of 1,182 common shares in early August 2026, with transactions occurring on August 3rd and 4th. source
• CEO Michael F. Mahoney purchased 186,240 shares of common stock in an open-market buy on August 3, 2026 at a weighted average price of $48.3323 per share. source